Alexion lifts revenue guidance on strong Soliris sales

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) raised its revenue guidance after reporting $636 million in Soliris eculizumab sales in 2Q15, which were up 24% from $512.5 million in 2Q14 and above analyst estimates of $628.5 million. The company also reported non-GAAP diluted EPS of $1.44, up 29% from $1.12 in 2Q14 and above the Street's estimate of $1.38.

Alexion edged up its 2015 revenue guidance from $2.55-$2.6 billion to $2.6-$2.62 billion to reflect growth in Soliris sales, which CEO David Hallal said compensated for the later ...